From the brink of collapse in early 2023, Philadelphia-based Context Therapeutics has staged one of biotech’s most remarkable turnarounds by boldly pivoting away from its original women’s oncology lead program—halted due to safety concerns—to a cutting-edge portfolio of T cell-engaging bispecific antibodies targeting solid tumors. With just a dozen employees, the company leveraged a quietly developed backup asset, CTIM-76, raised $100 million in fresh capital, and transformed itself from a single-asset outfit with a shrinking runway into a multi-asset powerhouse advancing first-in-human trials and acquiring promising clinical-stage bispecifics. Context’s story isn’t just about science; it’s a masterclass in survival, strategic optionality, operational discipline, and navigating one of biotech’s most brutal landscapes.

Transcript - http://empor.top/us/CNTX

• I. Introduction: A Philadelphia Biotech's Improbable Second Act
• II. The Founding Vision: Women's Oncology Meets Unmet Need
• III. The Pre-IPO Struggle: Building a Clinical Pipeline
• IV. IPO and Early Public Life: Momentum and Promise
• V. The Inflection Point: The ONA-XR Crisis
• VI. The Pivot: Betting Everything on CTIM-76
• VII. The Transformative Year: 2024 and the $100M Lifeline
• VIII. The Current Pipeline and Clinical Progress
• IX. Playbook: Biotech Survival and Pivot Lessons
• X. Porter's Five Forces and Hamilton's Seven Powers Analysis
• XI. Bear versus Bull Case
• XII. Key Performance Indicators to Track